Litigation Details for Cephalon, Inc. v. Sagent Pharmaceuticals Inc. (D. Del. 2014)

« Back to Dashboard

Cephalon, Inc. v. Sagent Pharmaceuticals Inc. (D. Del. 2014)

Docket		Date Filed	2014-09-02
Court	District Court, D. Delaware	Date Terminated	2016-08-29
Cause	35:271 Patent Infringement	Assigned To	Gregory Moneta Sleet
Jury Demand	None	Referred To
Patents	8,436,190; 8,445,524; 8,609,863; 8,791,270
Link to Docket	External link to docket

Details for Cephalon, Inc. v. Sagent Pharmaceuticals Inc. (D. Del. 2014)

Date Filed	Document No.	Description	Snippet	Link To Document
2014-09-02				External link to document

Cephalon v. Sagent Pharmaceuticals Patent Litigation: Treanda Generic Entry and Case Analysis

Last updated: September 29, 2026

Cephalon, Inc. v. Sagent Pharmaceuticals, Inc., No. 1:14-cv-01116, was a District of Delaware Hatch-Waxman action involving Sagent’s proposed generic version of Treanda, an injectable bendamustine hydrochloride product. Cephalon asserted U.S. Patent No. 8,445,466 after Sagent filed an Abbreviated New Drug Application and a Paragraph IV certification. The case was later terminated without a reported merits decision determining patent validity or infringement. The public record indicates a negotiated resolution rather than a trial judgment. [1]

What drug and patent were involved in Cephalon v. Sagent?

The litigation concerned Treanda, the branded injectable formulation of bendamustine hydrochloride used primarily in hematologic malignancies.

Item	Details
Brand	Treanda
Active ingredient	Bendamustine hydrochloride
Dosage form	Powder for injection requiring reconstitution
Brand sponsor at litigation	Cephalon, Inc., later part of Teva Pharmaceuticals
Generic applicant	Sagent Pharmaceuticals, Inc.
Court	U.S. District Court for the District of Delaware
Case number	1:14-cv-01116
Filed	2014
Patent asserted	U.S. Patent No. 8,445,466
Statutory framework	Hatch-Waxman Act
Disposition	Terminated without a reported adjudication on the merits

Cephalon became part of Teva in 2011. Although the complaint was filed in Cephalon’s name, the commercial and patent interests were ultimately connected to Teva’s Treanda franchise. [2]

What patents protect Treanda and bendamustine injection?

The principal patent identified in this action was U.S. Patent No. 8,445,466.

U.S. Patent No. 8,445,466

The patent covered aspects of bendamustine hydrochloride formulations and their use. The patent was assigned to or controlled by the Cephalon/Teva organization and was listed in the FDA’s Orange Book for Treanda-related products.

The patent’s listed expiration was in 2027, subject to any applicable patent-term adjustment or extension reflected in the official patent and Orange Book records. The asserted patent therefore extended materially beyond Treanda’s initial FDA exclusivity period.

The litigation did not establish, through a reported final judgment, whether the patent was valid, infringed, or enforceable against Sagent. No reported Delaware opinion from this action provides a definitive claim-construction or invalidity holding.

Formulation protection was the central barrier

The case was not principally a dispute over bendamustine’s chemical identity. Sagent’s product was a proposed generic injectable. The commercial dispute focused on patent rights associated with the formulation, preparation, or use of bendamustine hydrochloride in an injectable product.

For generic injectable oncology products, formulation claims can be commercially important even when the active ingredient is old. The generic applicant may need to address patents covering:

• The composition of the injectable product
• Stabilizers, excipients, or solvent systems
• Lyophilization or reconstitution
• Concentration and vial presentation
• Administration methods
• Treatment of specified cancers or patient populations

An Orange Book-listed formulation patent can trigger a statutory stay and create launch risk even when the active pharmaceutical ingredient is no longer protected by composition-of-matter exclusivity.

Why did Cephalon sue Sagent?

Cephalon sued after Sagent notified the patent owner that it had filed an ANDA containing a Paragraph IV certification against the asserted Treanda patent.

A Paragraph IV certification states that a listed patent is invalid, unenforceable, or will not be infringed by the proposed generic product. The notice gives the patent owner an opportunity to file an infringement action under 35 U.S.C. § 271(e)(2).

The filing of the action created the possibility of an FDA approval stay under 21 U.S.C. § 355(j)(5)(B)(iii). The stay can delay final FDA approval for up to 30 months, unless the court resolves the case earlier or the statutory stay is otherwise shortened or terminated.

The complaint therefore had two commercial effects:

1. It preserved Cephalon’s ability to enforce the listed patent.
2. It delayed or complicated Sagent’s path to final approval and commercial launch.

What was the procedural history of the case?

The public docket identifies the following basic chronology:

Date or period	Event
2014	Cephalon filed the infringement action in the District of Delaware
2014 onward	Sagent defended against the Paragraph IV patent claims
Subsequent proceedings	The parties litigated the patent dispute under the Hatch-Waxman framework
Before a reported merits judgment	The case was terminated
Final public outcome	No reported trial decision on validity, infringement, or enforceability

The available public record does not establish a reported claim-construction opinion, summary judgment decision, or trial verdict in the case. The termination therefore should not be characterized as a judicial finding that the patent was valid or infringed.

Was the case settled?

The case ended without a reported merits determination. That outcome is consistent with a negotiated resolution, although the publicly accessible docket materials do not provide a complete commercial description of the settlement terms.

The record does not support a conclusion that Sagent received an unrestricted right to launch immediately, nor does it establish a specific licensed-entry date. Hatch-Waxman settlements commonly address:

• The date on which the generic may launch
• Whether the launch is authorized or contingent
• Patent-license scope
• Supply arrangements
• Restrictions on product form or indication
• Acceleration provisions if the patent is invalidated
• Competition from other generic applicants

Absent a filed settlement agreement or public Federal Trade Commission analysis disclosing the terms, the economic provisions should be treated as confidential.

What was the Orange Book status of Treanda?

The Orange Book listed patent protection associated with Treanda and provided the basis for the infringement action. The relevant listing allowed Cephalon to assert the patent against an ANDA applicant that certified the patent was invalid or not infringed.

The Orange Book distinction between patents and regulatory exclusivity is important:

Protection	Relevance to Sagent
Patent listing	Created the basis for the Paragraph IV dispute
New-drug exclusivity	Covered the initial FDA approval period but was separate from the patent
Generic approval	Depended on FDA review, certification status, and resolution of the patent stay
Pediatric exclusivity	No public record in this action indicates that pediatric exclusivity controlled the dispute

FDA approval of a generic injectable product does not itself resolve the patent dispute. A product can receive tentative approval while final approval remains blocked by a patent stay or settlement restriction.

Did Sagent face a generic launch risk?

Yes. Sagent faced three principal launch risks.

Patent invalidity risk

If the court upheld the patent and found infringement, Sagent could have been blocked until patent expiration or an authorized launch date. The asserted patent’s long remaining term made an adverse judgment commercially significant.

Regulatory timing risk

The FDA approval process and the patent litigation operated separately. Sagent needed to satisfy chemistry, manufacturing, controls, labeling, and facility requirements in addition to resolving the Paragraph IV case.

Injectable oncology products carry higher manufacturing and quality risks than many oral solid-dose generics. Sterility, particulate control, container closure, reconstitution performance, and batch consistency can delay approval or complicate supply.

Commercial launch risk

Treanda had an established oncology market and hospital purchasing relationships. Sagent would have faced substitution, contracting, and reimbursement barriers even if it secured approval.

The product also competed with later bendamustine presentations, including ready-to-dilute or reduced-preparation products. A generic vial that required more preparation could have been commercially disadvantaged against products designed to reduce handling time and occupational exposure.

How strong was the Cephalon patent estate?

The patent estate was commercially meaningful but narrower than a broad composition-of-matter estate.

Strengths

• Orange Book listing created a direct Hatch-Waxman enforcement mechanism.
• The asserted patent extended beyond the initial Treanda regulatory exclusivity period.
• Injectable formulation claims can be difficult to design around without changing product performance.
• A successful infringement claim could delay generic entry for years.

Limitations

• The asserted patent did not provide perpetual control over bendamustine as a molecule.
• Formulation claims may face written-description, enablement, obviousness, or anticipation challenges.
• Generic applicants can sometimes design around excipient, concentration, or manufacturing limitations.
• No reported final decision in this case confirms the patent’s validity or enforceability.

The correct risk assessment is therefore “substantial but unadjudicated.” The litigation outcome did not create binding Delaware precedent validating the asserted patent.

Did the case involve a biosimilar?

No. This was a generic-drug case, not a biosimilar action.

Sagent proceeded through the ANDA pathway under Section 505(j) of the Federal Food, Drug, and Cosmetic Act. Bendamustine hydrochloride is a chemically synthesized small molecule, and the proposed product was evaluated as a generic injectable rather than under the Public Health Service Act’s biosimilar pathway.

The case therefore did not involve:

• A biologic reference product
• A biosimilar application
• The Biologics Price Competition and Innovation Act
• Patent lists under the biologics patent-exchange process
• Biosimilar interchangeability

Which companies challenged Treanda patents?

Sagent was one of multiple generic-drug companies that pursued opportunities in bendamustine or related injectable products. The competitive field included manufacturers with established hospital-generic operations and oncology portfolios.

The key competitive categories were:

Competitor type	Strategic position
ANDA applicants	Sought approval for generic bendamustine injection
Teva/Cephalon	Controlled the Treanda franchise and related patent rights
Specialty injectable manufacturers	Had manufacturing and hospital-distribution capabilities
Later formulation sponsors	Developed products intended to simplify administration or preparation

The existence of multiple applicants could weaken the settlement leverage of any single generic company. It could also reduce the exclusivity value of a first Paragraph IV filer if other applicants obtained alternative routes to approval.

What revenue exposure did the litigation create?

The case put Treanda sales at risk because an authorized or unauthorized generic could reduce net pricing and hospital purchasing leverage.

The exposure depended on:

• The timing of Sagent’s launch
• Whether Sagent obtained first-filer exclusivity
• The number of other approved or launch-ready generics
• Product substitution in oncology practices
• The success of newer bendamustine formulations
• Teva’s ability to shift demand within its oncology portfolio

Teva’s commercial response included lifecycle management of bendamustine products. Newer formulations could reduce dependence on the original Treanda presentation and preserve some value after generic entry. Patent litigation over the original formulation therefore formed part of a broader product lifecycle strategy rather than an isolated legal event. [2]

What manufacturing and intellectual-property barriers remained?

The most significant non-patent barriers were manufacturing and quality-related.

A generic bendamustine injectable manufacturer needed to address:

• Sterile manufacturing capacity
• Validated aseptic processes
• Stability during storage
• Reconstitution and dilution performance
• Vial and stopper compatibility
• Supply of active pharmaceutical ingredient
• FDA inspection readiness
• Labeling consistency with the reference product

A design-around could reduce infringement exposure but create regulatory comparability issues. Changing excipients, concentration, or reconstitution instructions may avoid a claim limitation while increasing the burden of demonstrating equivalent performance.

What does the case mean for generic launch analysis?

The case supports four conclusions.

First, an Orange Book-listed formulation patent can materially delay a generic injectable even when the active ingredient is established.

Second, termination of a Hatch-Waxman case does not establish that the patent survived a validity challenge. The absence of a merits decision limits the precedential value of the case.

Third, a confidential settlement can preserve uncertainty over launch timing, authorized-entry rights, and competitive restrictions.

Fourth, commercial entry depends on more than patent expiration. FDA approval, manufacturing readiness, hospital contracting, competing generics, and later-generation formulations can determine whether an approved applicant achieves meaningful market share.

Key Takeaways

• Cephalon v. Sagent, No. 1:14-cv-01116, involved Sagent’s ANDA for generic Treanda, or bendamustine hydrochloride injection.
• Cephalon asserted U.S. Patent No. 8,445,466.
• The dispute arose from Sagent’s Paragraph IV certification.
• The action was terminated without a reported decision on patent validity, infringement, or enforceability.
• The case was a Hatch-Waxman generic-drug dispute, not a biosimilar case.
• The patent estate created meaningful delay and launch risk, but the public record does not establish an adjudicated patent win.
• Injectable manufacturing, sterile production, FDA approval, and hospital contracting were material commercial barriers.
• The settlement terms and any authorized launch date were not publicly established in the available record.

FAQs About Cephalon v. Sagent Pharmaceuticals

What was the drug in Cephalon v. Sagent Pharmaceuticals?

The drug was Treanda, an injectable bendamustine hydrochloride product used in hematologic cancer treatment.

What patent did Cephalon assert against Sagent?

Cephalon asserted U.S. Patent No. 8,445,466 in the District of Delaware litigation.

Was Sagent’s generic bendamustine product approved by the FDA?

Sagent pursued FDA approval through the ANDA pathway. The litigation record alone does not establish the complete regulatory history or the precise date of any final approval.

Did Cephalon win the patent case?

The public record does not show a reported merits judgment awarding Cephalon a finding of infringement or upholding the patent. The case ended before such a reported decision.

When did Treanda lose patent exclusivity?

The asserted U.S. Patent No. 8,445,466 had a listed expiration in 2027, subject to the official patent and Orange Book records. Actual generic entry could occur earlier through settlement, license, invalidation, or other legal mechanisms.

References

1. U.S. District Court for the District of Delaware. (2014). Cephalon, Inc. v. Sagent Pharmaceuticals, Inc., No. 1:14-cv-01116. Civil docket and filings.

2. Teva Pharmaceutical Industries Ltd. (2014). Annual report pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934. U.S. Securities and Exchange Commission.

3. U.S. Food and Drug Administration. (2024). Approved drug products with therapeutic equivalence evaluations: Orange Book. U.S. Department of Health and Human Services.

4. United States Code. (2023). 21 U.S.C. § 355(j), abbreviated new drug applications and patent certifications.

5. United States Code. (2023). 35 U.S.C. § 271(e)(2), infringement relating to drug approval applications.